Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
July 28, 2022 07:00 ET
|
Sareum Holdings PLC
Sareum Holdings PLC (“Sareum” or the “Company”) Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update...